ClinicalTrials.gg
Not yet recruitingNCT07324460Updated Sep 22, 2026

One-Hour Positive Pressure Ventilation After a Pressure Support Spontaneous Breathing Trial

An interventional study of One-hour positive pressure ventilation and Immediate extubation in Airway Extubation, Weaning Mechanical Ventilation and Extubation Failure, sponsored by Hospital do Coracao. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Hospital do Coracao · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, open, multicenter, pragmatic, adaptive clinical trial with intention-to-treat analysis. The study will compare two weaning strategies from mechanical ventilation in critically ill patients admitted to intensive care units, with more than 72 hours of mechanical ventilation and with a successful spontaneous breathing trial on pressure support. Immediately after a successful spontaneous breathing trial, eligible patients will be randomized into 2 groups that will be treated according to one of the following interventions:1) One-hour positive pressure ventilation: as soon as the success of the spontaneous breathing trial is confirmed, the patient is submitted to mechanical ventilation for 1 hour using the previous ventilatory parameters and, afterwards, extubated.2) Immediate extubation: the patient is extubated immediately after the success of the spontaneous breathing trial.

Read the detailed description

Adaptive design for sample size. The study will include up to a maximum of 4.000 patients. First interim analysis will be performed after complete data is available for the first 500 eligible patients. The Bayesian logistic regression model will be adjusted to provide posterior probabilities that will be compared with threshold values to evaluate stopping decisions. Extensive simulations were conducted to develop and understand adaptive design performance, interim analysis timing, and decision criteria. The trial may be stopped early for efficacy or futility. Secondary outcomes will be analyzed with a gatekeeping procedure to preserve overall type I error at 0.05. Thus, the assessment of statistical significance of secondary outcomes will be performed only if the preceding outcome in the hierarchy met the threshold for statistical significance. No adjustment for multiple comparisons will be applied for analyses of tertiary outcomes and subgroups. Thus, these results should be interpreted as exploratory.Secondary outcomes tested in hierarchical order will be: (1) Mechanical ventilation free days within 28 days; (2) Hospital free days within 28 days; (3) Mortality within 28 days.

02

Conditions studied

  • Airway Extubation
  • Weaning Mechanical Ventilation
  • Extubation Failure

Keywords

  • Airway extubation
  • Weaning Mechanical Ventilation
  • Extubation failure
03

In context

Lead sponsor

Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged > 18 years.
  • Admitted to the intensive care unit (surgical or medical).
  • With endotracheal intubation.
  • Mechanical ventilation for more than 72 hours.
  • Who underwent successful spontaneous breathing trial (according to the study protocol) and is considered able to be extubated.

Exclusion criteria

Exclusion Criteria:

  • Patients unable to obey commands.
  • With non-planned extubation.
  • Neuromuscular disease and cervical spinal cord injury.
  • Tracheostomy.
  • for cardiopulmonary resuscitation or reintubation.
  • Terminal extubation.
  • Lack of .
  • Previously included in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,000 participants (estimated)

Study arms

  • Experimental
    One-hour positive pressure ventilation

    Other: One-hour positive pressure ventilation

  • Active comparator
    Immediate extubation

    Other: Immediate extubation

Interventions

  • OtherOne-hour positive pressure ventilation

    As soon as the success of the spontaneous breathing trial is confirmed, the patient will be submitted to one-hour positive pressure ventilation using the previous ventilatory parameters and, afterwards, extubated.

  • OtherImmediate extubation

    The patient will be extubated immediately (up to 10 minutes) after the success of the spontaneous breathing trial.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Extubation Failure Within 7 Days

    Extubation failure is defined as a composite endpoint of reintubation or death within 7 days after randomization

    Time frame: 7 days (from randomization through Day 7 after randomization)

Secondary outcomes

  1. Ventilator-Free Days Through Day 28

    Ventilator-free days are defined as the number of days alive and free from invasive mechanical ventilation from randomization through Day 28 after randomization. If a patient dies before day 28, the ventilator-free days will be counted as zero. If a patient is reintubated and returns to mechanical ventilation and later is extubated again and remains in unassisted breathing until day 28, the ventilator-free days will be counted from the end of the last period of assisted breathing until day 28. An invasive mechanical ventilation period of less than 24 hours for surgical purposes will count as 1 ventilator-free day. Patients discharged from the hospital in unassisted breathing before 28 days will be considered alive and free from mechanical ventilation for the remaining days up to 28 days. Patients transferred to another hospital or healthcare unit will be followed up until day 28 to assess this outcome.

    Time frame: 28 days (from randomization through Day 28 after randomization)

  2. Hospital-Free Days Through Day 28

    Hospital-free days are defined as the number of days alive and out of the hospital from randomization through Day 28 after randomization. If a patient dies before day 28, the hospital-free days will be counted as zero. Patients discharged from the hospital in unassisted breathing before 28 days will be considered alive and free from hospital for the remaining days up to 28 days. Patients transferred to another hospital or healthcare unit will be followed through day 28 to ascertain this outcome.

    Time frame: 28 days (from randomization through Day 28 after randomization)

  3. Number of Participants Who Died Within 28 Days

    All-cause mortality from randomization through day 28

    Time frame: 28 days (from randomization through Day 28 after randomization)

Other outcomes

  1. Ventilatory Support-Free Days Through Day 28

    Ventilatory support-free days are defined as the number of days alive and free from any ventilatory support (invasive or noninvasive) from randomization through day 28. Any use of invasive mechanical ventilation for any duration during a calendar day will count as 1 day with ventilatory support (i.e., not free). Use of noninvasive ventilatory support (noninvasive ventilation or high-flow nasal cannula) for ≥6 hours in any calendar day will count as 1 day with ventilatory support. Participants who die before day 28 will be assigned 0 ventilatory support-free days. If reintubation occurs and the participant later achieves unassisted spontaneous breathing again, ventilatory support-free days will be counted from the end of the last assisted-breathing period through day 28, provided the participant remains alive and free from ventilatory support.

    Time frame: 28 days (from randomization through Day 28 after randomization)

  2. Number of Participants With Extubation Failure Within 2 Days

    Extubation failure is defined as a composite endpoint of reintubation or death within 2 days after randomization

    Time frame: 2 days (from randomization through Day 2 after randomization)

  3. Number of Participants With Death or Reintubation Within 28 Days

    Composite endpoint of reintubation or death within 28 days after randomization

    Time frame: 28 days (from randomization through Day 28 after randomization)

  4. Intensive Care Unit-Free Days Through Day 28

    ICU-free days are defined as the number of days alive and out of the intensive care unit from randomization through day 28. If a patient dies before day 28, the ICU-free days will be counted as zero. Patients discharged from the hospital in unassisted breathing before 28 days will be considered as alive and free from ICU for the remaining days up to 28 days. Patients transferred to another hospital or healthcare unit will be followed up until day 28 to assess this outcome.

    Time frame: 28 days (from randomization through Day 28 after randomization)

  5. Number of Participants Who Died in the Intensive Care Unit

    All-cause mortality occurring from randomization until ICU discharge (death before ICU discharge)

    Time frame: From randomization to ICU discharge, up to 90 days

  6. Number of Participants Who Died in the Hospital

    All-cause mortality occurring from randomization until hospital discharge (death before hospital discharge)

    Time frame: From randomization to hospital discharge, up to 90 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 7, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2029
CompletionEst.
Feb 2030
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07324460
Lead sponsor
Hospital do Coracao
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Feb 2030 (estimated)
Last update
Sep 22, 2026

Study contacts

Aline B Pereira
Contact
linibp@hotmail.com
+55 (47) 99181-8400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion